2:26-cv-06562
Incyte Corp v. Zydus Lifesciences Ltd
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Incyte Corp. and Incyte Holdings Corporation (Delaware)
- Defendant: Zydus Lifesciences Ltd. (India)
- Plaintiff's Counsel: Saul Ewing LLP
- Case Identification: 2:26-cv-06562, D.N.J., 08/10/2026
- Venue Allegations: Venue is alleged to be proper as Defendant is a foreign corporation that may be sued in any judicial district and has purposefully availed itself of the rights and benefits of New Jersey by asserting counterclaims in the court.
- Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's Opzelura® (ruxolitinib) cream constitutes an act of infringement of nine U.S. patents covering topical pharmaceutical formulations.
- Technical Context: The technology relates to topical formulations of ruxolitinib, a Janus kinase (JAK) inhibitor, for the treatment of skin disorders such as atopic dermatitis and vitiligo.
- Key Procedural History: This action arises under the Hatch-Waxman Act, triggered by Defendant's submission of ANDA No. 218568 with a Paragraph IV Certification. The certification alleges that Plaintiff's patents are invalid and/or will not be infringed by Defendant's proposed generic product. The complaint notes that this is a First Amended Complaint and that a prior suit involving other patents was filed against Defendant in the same court.
Case Timeline
| Date | Event |
|---|---|
| 2010-05-21 | Earliest Patent Priority Date (''543, ''870, ''624, ''425, ''136, ''419, ''381, ''593, ''096 Patents) |
| 2020-09-01 | '543 Patent Issued |
| 2020-12-22 | '870 Patent Issued |
| 2022-01-11 | '624 Patent Issued |
| 2023-02-07 | '425 Patent Issued |
| 2023-02-28 | '136 Patent Issued |
| 2025-02-18 | '419 Patent Issued |
| 2026-02-10 | '381 Patent Issued |
| 2026-03-03 | '593 Patent Issued |
| 2026-03-31 | '096 Patent Issued |
| 2026-04-22 | Alleged date of Zydus's Second Notice Letter to Incyte |
| 2026-07-23 | Alleged date of Zydus's Third Notice Letter to Incyte |
| 2026-08-10 | Complaint Filing Date |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 10,758,543 - "Topical Formulation for a JAK Inhibitor"
- Patent Identification: U.S. Patent No. 10,758,543, "Topical Formulation for a JAK Inhibitor", Issued September 1, 2020.
The Invention Explained
- Problem Addressed: The patent background describes a need for improved topical formulations of Janus kinase (JAK) inhibitors for treating skin disorders, noting a specific need for formulations that are stable, easily applied, and have good skin permeation characteristics '543 Patent, col. 2:32-38
- The Patented Solution: The patent discloses an oil-in-water emulsion formulation containing the JAK inhibitor (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, also known as ruxolitinib '543 Patent, abstract The detailed description states these formulations exhibit good spreadability and stability, which is believed to result in better skin permeation compared to anhydrous or water-in-oil alternatives '543 Patent, col. 4:30-42 A flowchart in the patent illustrates the manufacturing process for the formulation '543 Patent, Fig. 1
- Technical Importance: Developing a stable and effective topical delivery system for a JAK inhibitor was significant for treating inflammatory skin disorders like psoriasis, where signaling through the JAK/STAT pathway is implicated in the disease pathology '543 Patent, col. 2:15-30
Key Claims at a Glance
- The complaint alleges infringement of "one or more claims" without specifying them Compl. ¶40 Independent claim 1 is representative of the patented composition.
- Claim 1 of the '543 Patent requires:
- A pharmaceutical composition suitable for topical skin application;
- Comprising an oil-in-water emulsion that includes water, an oil component, an emulsifier component, and a solvent component;
- The emulsion contains from about 0.5% to about 1.5% by weight of ruxolitinib phosphoric acid salt (on a free base basis);
- The oil-in-water emulsion is a "solubilized cream";
- The oil-in-water emulsion has a pH of not greater than 3.6.
U.S. Patent No. 10,869,870 - "Topical Formulation for a JAK Inhibitor"
- Patent Identification: U.S. Patent No. 10,869,870, "Topical Formulation for a JAK Inhibitor", Issued December 22, 2020.
The Invention Explained
- Problem Addressed: The '870 Patent addresses the same technical problem as the '543 Patent: the need for improved topical formulations of JAK inhibitors for treating skin disorders ('870 Patent, col. 2:32-38).
- The Patented Solution: The '870 Patent claims a method of treating a skin disorder by applying the same oil-in-water emulsion formulation of ruxolitinib described in the '543 Patent '870 Patent, abstract '870 Patent, col. 3:7-20 The patent describes the formulation as a "solubilized cream" suitable for topical application to treat autoimmune skin disorders '870 Patent, col. 39:50-53 '870 Patent, col. 43:5-13
- Technical Importance: This patent extends protection from the composition itself to the method of using that specific composition to treat skin disorders, a common strategy to broaden the scope of patent coverage for a pharmaceutical product.
Key Claims at a Glance
- The complaint alleges infringement of "one or more claims" Compl. ¶49 Independent claim 1 is representative of the patented method.
- Claim 1 of the '870 Patent requires:
- A method of treating a skin disorder in a human patient;
- Applying a pharmaceutically acceptable composition that is an oil-in-water emulsion;
- The emulsion comprises water, an oil component, an emulsifier component, and a solvent component;
- The emulsion contains from about 0.5% to about 1.5% by weight of ruxolitinib phosphoric acid salt (on a free base basis);
- The oil-in-water emulsion is a "solubilized cream";
- The emulsion has a pH of not greater than 3.6;
- The treating step inhibits or ameliorates the skin disorder, which is an autoimmune skin disorder.
Multi-Patent Capsules
U.S. Patent No. 11,219,624: Entitled "Topical Formulation for a JAK Inhibitor" and issued on January 11, 2022 '624 Patent Compl. ¶7 The patent describes and claims a pharmaceutical composition as a "solubilized cream" containing a specific oil-in-water emulsion of ruxolitinib phosphate for topical application '624 Patent, abstract The asserted independent claims are not specified, but the complaint alleges that Zydus's Proposed Generic Product will infringe '624 Patent Compl. ¶¶56, 58
U.S. Patent No. 11,571,425: Entitled "Topical Formulation for a JAK Inhibitor" and issued on February 7, 2023 '425 Patent Compl. ¶8 The patent describes and claims a topical pharmaceutical formulation comprising an oil-in-water emulsion of ruxolitinib for treating skin disorders '425 Patent, abstract The asserted independent claims are not specified, but the complaint alleges that Zydus's Proposed Generic Product will infringe '425 Patent Compl. ¶¶65, 67
U.S. Patent No. 11,590,136: Entitled "Topical Formulation for a JAK Inhibitor" and issued on February 28, 2023 '136 Patent Compl. ¶9 This patent claims methods of treating atopic dermatitis by applying a topical formulation of ruxolitinib '136 Patent, abstract The asserted independent claims are not specified, but the complaint alleges that the intended use of Zydus's Proposed Generic Product will infringe '136 Patent Compl. ¶¶74, 76
U.S. Patent No. 12,226,419: Entitled "Topical Formulation for a JAK Inhibitor" and issued on February 18, 2025 '419 Patent Compl. ¶10 The patent claims methods of reducing itch in patients with atopic dermatitis by applying a topical ruxolitinib formulation '419 Patent, abstract The asserted independent claims are not specified, but the complaint alleges that the intended use of Zydus's Proposed Generic Product will infringe '419 Patent Compl. ¶¶83, 85
U.S. Patent No. 12,544,381: Entitled "Topical Formulation for a JAK Inhibitor" and issued on February 10, 2026 '381 Patent Compl. ¶11 This patent claims methods of treating atopic dermatitis by applying a topical ruxolitinib formulation that achieves specific efficacy endpoints, such as an Investigator's Global Assessment (IGA) score of 0 or 1 '381 Patent, abstract The asserted independent claims are not specified, but the complaint alleges that the intended use of Zydus's Proposed Generic Product will infringe '381 Patent Compl. ¶¶92, 94
U.S. Patent No. 12,564,593: Entitled "Topical Formulation for a JAK Inhibitor" and issued on March 3, 2026 '593 Patent Compl. ¶12 This patent claims oil-in-water emulsion formulations of ruxolitinib with specific component requirements '593 Patent, abstract The asserted independent claims are not specified, but the complaint alleges that Zydus's Proposed Generic Product will infringe '593 Patent Compl. ¶¶101, 103
U.S. Patent No. 12,589,096: Entitled "Ruxolitinib Formulation for Reduction of Itch in Atopic Dermatitis" and issued on March 31, 2026 '096 Patent Compl. ¶13 The patent claims methods of reducing itch by administering a 0.75% or 1.5% topical ruxolitinib cream '096 Patent, abstract The asserted independent claims are not specified, but the complaint alleges that the intended use of Zydus's Proposed Generic Product will infringe '096 Patent Compl. ¶¶110, 112
III. The Accused Instrumentality
Product Identification
- The accused instrumentality is "Zydus's Proposed Generic Product," a generic version of Incyte's Opzelura® (ruxolitinib) cream, which is the subject of ANDA No. 218568 Compl. ¶1 Compl. ¶23
Functionality and Market Context
- The complaint alleges that Zydus seeks FDA approval to manufacture and sell a generic equivalent of Opzelura® cream Compl. ¶1 Opzelura® is an approved drug product for, among other things, the topical treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo Compl. ¶14 Compl. ¶¶17-18 The infringement allegation is predicated on the act of filing the ANDA itself, which seeks approval for a drug product that, by law, must have the same active ingredient, dosage form, and strength as the branded Opzelura® product, and whose proposed label will allegedly instruct for infringing uses Compl. ¶19 Compl. ¶38
IV. Analysis of Infringement Allegations
No probative visual evidence provided in complaint.
The core of the infringement allegation under the Hatch-Waxman Act is the submission of the ANDA itself, which is a technical act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶38 The complaint does not provide a detailed breakdown of how the accused product meets each claim limitation, as this information is contained within Zydus's confidential ANDA. The infringement theory is that the proposed generic product will necessarily have the same composition and be used for the same methods as the patented invention.
'543 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A pharmaceutical composition suitable for topical skin application, | Zydus's Proposed Generic Product is alleged to be a pharmaceutical composition for topical application Compl. ¶23 | ¶¶38, 40 | col. 7:4-6 |
| comprising: an oil-in-water emulsion, comprising: water; an oil component; an emulsifier component; a solvent component; | Zydus's Proposed Generic Product is alleged to be an oil-in-water emulsion containing these components, mirroring the formulation of Opzelura® Compl. ¶1 Compl. ¶14 | ¶¶38, 40 | col. 4:20-24 |
| and from about 0.5% to about 1.5% by weight of the emulsion on a free base basis of 1:1 (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl-]propanenitrile phosphoric acid salt, | Zydus's Proposed Generic Product is alleged to contain ruxolitinib phosphate salt within the claimed concentration range Compl. ¶23 | ¶¶38, 40 | col. 8:55-63 |
| wherein the oil-in-water emulsion in the composition is a solubilized cream for topical skin application | Zydus's Proposed Generic Product is alleged to be a solubilized cream, as it is a generic version of Opzelura® cream Compl. ¶1 Compl. ¶14 | ¶¶38, 40 | col. 39:50-53 |
| and further wherein the oil-in-water emulsion has a pH of not greater than 3.6. | Zydus's Proposed Generic Product is alleged to have a pH meeting this limitation Compl. ¶23 | ¶¶38, 40 | col. 39:62-63 |
'870 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method of treating a skin disorder in a human patient in need thereof, comprising: applying to the patient's skin a pharmaceutically acceptable composition... | The proposed labeling for Zydus's product is alleged to instruct physicians and patients to apply the product to treat skin disorders like atopic dermatitis (Compl. ¶17; Compl. ¶19). | ¶¶49-50 | col. 15:26-29 |
| [composition comprising an oil-in-water emulsion... with 0.5% to 1.5% ruxolitinib phosphate salt] | As described in the analysis of the '543 Patent, Zydus's Proposed Generic Product is alleged to be a composition meeting these limitations Compl. ¶23 Compl. ¶47 | ¶¶49-50 | col. 39:50-63 |
| wherein the oil-in-water emulsion in the composition is a solubilized cream... and has a pH of not greater than 3.6; | Zydus's Proposed Generic Product is alleged to be a solubilized cream with a pH meeting this limitation Compl. ¶23 Compl. ¶47 | ¶¶49-50 | col. 39:50-63 |
| wherein treating is one or more of inhibiting the skin disorder and ameliorating the skin disorder; and wherein the skin disorder is an autoimmune skin disorder. | The FDA-approved indications for Opzelura®, which Zydus's product is intended to copy, include autoimmune skin disorders such as atopic dermatitis (Compl. ¶17). | ¶¶49-50 | col. 15:26-29 |
- Identified Points of Contention:
- Scope Questions: The infringement analysis for the composition claims will depend on the definition of terms like "solubilized cream". The patents distinguish this form from others, such as dispersed creams, suggesting its meaning could be a point of dispute '543 Patent, col. 32:44-52 The definition of the various formulation "components" (e.g., "oil component", "emulsifier component") and whether Zydus's chosen excipients fall within their scope will also be critical.
- Technical Questions: A primary question for the court will be a factual comparison of Zydus's confidential ANDA formulation against the claim limitations. Zydus's non-infringement defense, noted in its Paragraph IV certification, suggests there may be a technical mismatch, for example, in the specific percentages of ingredients, the identity of the excipients, or the final formulation's pH Compl. ¶33 For the method claims, the dispute will turn on whether Zydus's proposed label induces infringement by instructing users to perform the claimed methods Compl. ¶19 Compl. ¶50
V. Key Claim Terms for Construction
The Term: "solubilized cream"
Context and Importance: This term appears in the independent claims of many of the asserted patents (e.g., '543 Patent, claim 1; '870 Patent, claim 1) and is central to defining the invention. A finding that Zydus's proposed generic is not a "solubilized cream" could support a non-infringement defense. Practitioners may focus on this term because the patents contrast it with other formulation types, such as "water-in-oil" or "anhydrous" formulations, implying it has a specific technical meaning related to the dissolution state of the active ingredient '543 Patent, col. 4:56-65
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The specification describes the "solubilized cream" in functional terms, noting it has a "thick, creamy appearance which allows for good spreadability" and leads to "better skin permeation" ('543 Patent, col. 4:30-34). This could support an interpretation based on the formulation's physical properties and performance rather than a strict compositional recipe.
- Evidence for a Narrower Interpretation: The patent provides specific examples of the "solubilized cream" formulation, detailing the identity and percentage of each component '543 Patent, Tables 2-5 A defendant may argue that the term should be limited to the specific embodiments disclosed, particularly the use of certain solvents like propylene glycol and polyethylene glycol to dissolve the ruxolitinib phosphate salt '543 Patent, col. 8:29-41
The Term: "pH of not greater than 3.6"
Context and Importance: This quantitative limitation is a critical boundary for infringement of claims in patents like the '543 and '870. If the pH of Zydus's product is proven to be higher than 3.6, infringement may be avoided.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The claim language provides a clear upper limit. A plaintiff would argue that any formulation with a measured pH at or below 3.6 literally infringes. The patent describes this low pH as an important feature, linking it to the stability and efficacy of the formulation.
- Evidence for a Narrower Interpretation: While the number itself is clear, a potential dispute could arise over the methodology for measuring the pH. The patent's examples show measured pH values of 3.1, 3.3, and 3.6 for different batches '543 Patent, Table 6 A party could argue that the term should be construed in light of the specific testing conditions used to generate the data in the patent, although challenging a plain numerical limit is difficult.
VI. Other Allegations
- Indirect Infringement: The complaint alleges inducement of infringement, stating that upon approval of its ANDA, Zydus will intentionally encourage acts of direct infringement by physicians, pharmacists, and patients Compl. ¶41 Compl. ¶50 This encouragement is alleged to occur through Zydus's marketing and the product's prescribing information, which will instruct on the patented methods of use Compl. ¶19 The complaint also pleads contributory infringement, alleging Zydus's product is especially adapted for an infringing use and has no substantial non-infringing use Compl. ¶42 Compl. ¶51
- Willful Infringement: The complaint does not use the term "willful infringement." It does, however, allege that each count represents an "exceptional one" and seeks an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶45 Compl. ¶54 The basis for this allegation is Zydus's submission of the ANDA with knowledge of the patents-in-suit, as evidenced by the Paragraph IV certification notice letters sent to Incyte Compl. ¶34 Compl. ¶36
VII. Analyst's Conclusion: Key Questions for the Case
- A central issue will be one of claim construction and scope: can the term "solubilized cream", which the patents distinguish from other formulations, be interpreted to encompass the specific combination of excipients and the physical state of the active ingredient in Zydus's proposed generic product?
- A key evidentiary question will be one of literal infringement: does Zydus's confidential ANDA specify a formulation that meets every numerical limitation of the asserted claims, including the specific weight percentages of the active ingredient and the formulation's "pH of not greater than 3.6"?
- A dispositive issue for the litigation will be validity: can Zydus prove by clear and convincing evidence that the asserted claims are invalid, likely on grounds of obviousness over prior art topical formulations or lack of adequate written description for the claimed range of compositions? Zydus's Paragraph IV letters allege invalidity, making this a core of its defense Compl. ¶33